PET imaging of colorectal and breast cancer by targeting EphB4 receptor with 64Cu-Labeled hAb47 and hAb131 antibodies

Journal of Nuclear Medicine

Volumn 54, Issue 7, 2013, Pages 1094-1100

  Liu, Shuanglong ^a   Li, Dan ^a,b   Park, Ryan ^a   Liu, Ren ^c   Xia, Zanxian ^d   Guo, Jiacong ^a   Krasnoperov, Valery ^d   Gill, Parkash S ^c   Li, Zibo ^a   Shan, Hong ^b   Conti, Peter S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d Vasgene Therapeutics Inc   (United States)

Author keywords

64Cu; Breast cancer; Colorectal cancer; EphB4; PET

Indexed keywords

EPHRIN RECEPTOR B4; MONOCLONAL ANTIBODY HAB131 CU 64; MONOCLONAL ANTIBODY HAB47 CU 64; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; COLORECTAL CANCER; CONJUGATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOCHEMISTRY; RECEPTOR BINDING; TUMOR XENOGRAFT;

64CU; BREAST CANCER; COLORECTAL CANCER; EPHB4; PET;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; COPPER RADIOISOTOPES; FEMALE; HT29 CELLS; HUMANS; ISOTOPE LABELING; MICE; MICE, NUDE; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, EPHB4; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84879918367     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.116822     Document Type: Article

References (36)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Coleman RE, Smith P, Rubens RD. Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer. 1998;77:336-340.
3. Bombardieri E, Gianni L. The choice of the correct imaging modality in breast cancer management. Eur J Nucl Med Mol Imaging. 2004;31(suppl 1):S179-S186.
4. Dodelet VC, Pasquale EB. Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene. 2000;19:5614-5619.
5. Erber R, Eichelsbacher U, Powajbo V, et al. EphB4 controls blood vascular morphogenesis during postnatal angiogenesis. EMBO J. 2006;25:628-641.
6. Wang HU, Chen ZF, Anderson DJ. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell. 1998;93:741-753.
7. Kumar SR, Singh J, Xia G, et al. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol. 2006;169:279-293.
8. Kumar SR, Scehnet JS, Ley EJ, et al. Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression. Cancer Res. 2009;69:3736-3745.
9. Stephenson SA, Slomka S, Douglas EL, Hewett PJ, Hardingham JE. Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer. BMC Mol Biol. 2001;2:15.
10. LiuW, Ahmad SA, Jung YD, et al. Coexpression of ephrin-Bs and their receptors in colon carcinoma. Cancer. 2002;94:934-939.
11. Xia G, Kumar SR, Stein JP, et al. EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival. Oncogene. 2006;25:769-780.
12. Xia G, Kumar SR, Masood R, et al. EphB4 expression and biological significance in prostate cancer. Cancer Res. 2005;65:4623-4632.
13. Lee YC, Perren JR, Douglas EL, et al. Investigation of the expression of the EphB4 receptor tyrosine kinase in prostate carcinoma. BMC Cancer. 2005;5:119.
14. Castellano G, Reid JF, Alberti P, Carcangiu ML, Tomassetti A, Canevari S. New potential ligand-receptor signaling loops in ovarian cancer identified in multiple gene expression studies. Cancer Res. 2006;66:10709-10719.
15. Kumar SR, Masood R, Spannuth WA, et al. The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br J Cancer. 2007;96:1083-1091.
16. Noren NK, Pasquale EB. Paradoxes of the EphB4 receptor in cancer. Cancer Res. 2007;67:3994-3997.
17. Krasnoperov V, Kumar SR, Ley E, et al. Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth. Am J Pathol. 2010;176:2029-2038.
18. Li ZB, Cai W, Cao Q, et al. 64Cu-labeled tetrameric and octameric RGD peptides for small-animal PETof tumor avb3 integrin expression. J Nucl Med. 2007;48:1162-1171.
19. Liu S, Li D, Huang CW, et al. Efficient construction of PET/fluorescence probe based on sarcophagine cage: an opportunity to integrate diagnosis with treatment. Mol Imaging Biol. 2012;14:718-724.
20. Liu S, Li Z, Yap LP, Huang CW, Park R, Conti PS. Efficient preparation and biological evaluation of a novel multivalency bifunctional chelator for 64Cu radiopharmaceuticals. Chemistry. 2011;17:10222-10225.
21. Wu Y, Zhang X, Xiong Z, et al. microPET imaging of glioma integrin avb3 expression using 64Cu-labeled tetrameric RGD peptide. J Nucl Med. 2005;46:1707-1718.
22. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 2011;17:1359-1370.
23. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39-51.
24. McKenney JK, Weiss SW, Folpe AL. CD31 expression in intratumoral macrophages: a potential diagnostic pitfall. Am J Surg Pathol. 2001;25:1167-1173.
25. Curat CA, Wegner V, Sengenes C, et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia. 2006;49:744-747.
26. Cai W, Rao J, Gambhir SS, Chen X. How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther. 2006;5:2624-2633.
27. Koolpe M, Burgess R, Dail M, Pasquale EB. EphB receptor-binding peptides identified by phage display enable design of an antagonist with ephrin-like affinity. J Biol Chem. 2005;280:17301-17311.
28. Xiong C, Huang M, Zhang R, et al. In vivo small-animal PET/CT of EphB4 receptors using 64Cu-labeled peptide. J Nucl Med. 2011;52:241-248.
29. Zhang R, Xiong C, Huang M, et al. Peptide-conjugated polymeric micellar nanoparticles for dual SPECT and optical imaging of EphB4 receptors in prostate cancer xenografts. Biomaterials. 2011;32:5872-5879.
30. Kaur S, Venktaraman G, Jain M, Senapati S, Garg PK, Batra SK. Recent trends in antibody-based oncologic imaging. Cancer Lett. 2012;315:97-111.
31. Deisenhofer J, Colman PM, Epp O, Huber R. Crystallographic structural studies of a human Fc fragment. II. A complete model based on a Fourier map at 3.5 A resolution. Hoppe Seylers Z Physiol Chem. 1976;357:1421-1434.
32. Silverton EW, Navia MA, Davies DR. Three-dimensional structure of an intact human immunoglobulin. Proc Natl Acad Sci USA. 1977;74:5140-5144.
33. Ashwell G, Morell AG. The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv Enzymol Relat Areas Mol Biol. 1974;41:99-128.
34. Stahl PD, Rodman JS, Miller MJ, Schlesinger PH. Evidence for receptor-mediated binding of glycoproteins, glycoconjugates, and lysosomal glycosidases by alveolar macrophages. Proc Natl Acad Sci USA. 1978;75:1399-1403.
35. Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem. 1982;51:531-554.
36. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65:271-284.